Dimethoxy(methyl)silane | CAS:16881-77-9

We serve Dimethoxy(methyl)silane CAS:16881-77-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Dimethoxy(methyl)silane

Chemical Name:Dimethoxy(methyl)silane
CAS.NO:16881-77-9
Synonyms:DiMethoxy(Methyl)silane; Silane, dimethoxymethyl-; 
Methyldimethoxysilane; Dimethoxymethylsilane;
Molecular Formula:C3H10O2Si
Molecular Weight:106.19600
 
Physical and Chemical Properties:
Density:0.861;
Melting point:-136oC;
Boiling point:61oC;
Flash point:35oC;
Index of Refraction:1.3600;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥98.0%
 
Packing:170 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used as an intermediate for other functional organosilanes.



Contact us for information like Dimethoxy(methyl)silane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dimethoxymethylsilane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dimethoxy(methyl)silane Use and application,Dimethoxy(methyl)silane technical grade,usp/ep/jp grade.


Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.Methyl 4-Hydroxy-2H-1,2-benzothiazine-3-carboxylate 1,1-Dioxide manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.2-(4-bromophenyl)triphenylene supplier Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities.L-alpha-Amino-n-butyric acid vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.